Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
NCT04018872
Summary
Esophageal cancer, which has a low 5-year overall survival rate for all stages (\<20%) , is increasing in incidence. Previous studies have shown that the Hedgehog (Hh) and AKT signaling pathways are activated in a significant proportion of esophageal cancers. Itraconazole, a widely used anti-fungal medication, has been shown to inhibit various pathways involved in esophageal cancer tumorigenesis including Hh and AKT. In this phase II clinical trial, the investigators aim to evaluate the effect of itraconazole as a neoadjuvant therapy following standard of care chemoradiation in the treatment of locoregional esophageal and gastroesophageal junction carcinomas.
Eligibility
Inclusion Criteria: * Patients diagnosed with localized (locoregional) esophageal cancer * Patients diagnosed with localized (locoregional) gastroesophageal junction cancer Exclusion Criteria: * Patients unwilling or unable to provide informed consent * Patients with QTc\>450ms * Patients with a history of symptomatic congestive heart failure * Patients with LFT's\>3xULN * Patients who are pregnant * Patients with a known allergy to itraconazole
Conditions4
Interventions1
Locations1 site
Find trials near these locations
Related trials
- Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer — AstraZeneca
- Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors — Hansoh BioMedical R&D Company
- Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer — Jiangsu HengRui Medicine Co., Ltd.
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors — BioNTech SE
- A Study of LY4170156 in Participants With Selected Advanced Solid Tumors — Eli Lilly and Company
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors — DualityBio Inc.
- A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma — Pfizer
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors — DualityBio Inc.
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT04018872